{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:15:26Z","timestamp":1794071726188,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA244667"],"award-info":[{"award-number":["R01CA244667"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210363"],"award-info":[{"award-number":["W81XWH2210363"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Androgen receptor (AR) overexpression is a key mechanism driving the development of castration-resistant prostate cancer (CRPC). This can result from multiple factors, including enhanced AR transcription and increased stability of AR mRNA and protein. In clinical CRPC samples, one cause of AR overexpression is gene amplification at the AR locus, which leads to elevated AR transcript and protein levels. In addition, increased activity or copy number of enhancer elements near the AR gene has been associated with elevated AR transcription. These regulatory regions interact with the AR gene promoter through enhancer\u2013promoter looping, thereby enhancing AR mRNA transcription. Elucidating the role of these enhancer elements in driving AR overexpression and aberrant AR signaling may uncover new therapeutic targets for CRPC.<\/jats:p>","DOI":"10.1038\/s12276-025-01624-9","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:48:16Z","timestamp":1768546096000},"page":"94-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulation of androgen receptor expression by enhancer elements in prostate cancer"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0610-7745","authenticated-orcid":false,"given":"Sudeep","family":"Khadka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-7094","authenticated-orcid":false,"given":"Hee-Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"1624_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1624_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33\u201339 (2004).","journal-title":"Nat. Med."},{"key":"1624_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"1624_CR4","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1530\/JME-11-0018","volume":"47","author":"M Shiota","year":"2011","unstructured":"Shiota, M., Yokomizo, A. & Naito, S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J. Mol. Endocrinol. 47, R25\u2013R41 (2011).","journal-title":"J. Mol. Endocrinol."},{"key":"1624_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115312","volume":"44","author":"RR Xiang","year":"2025","unstructured":"Xiang, R. R. et al. CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. Cell Rep. 44, 115312 (2025).","journal-title":"Cell Rep."},{"key":"1624_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","volume":"174","author":"DY Takeda","year":"2018","unstructured":"Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell 174, 422\u2013432 (2018).","journal-title":"Cell"},{"key":"1624_CR7","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ajhg.2021.11.007","volume":"108","author":"C Giambartolomei","year":"2021","unstructured":"Giambartolomei, C. et al. H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility. Am. J. Hum. Genet. 108, 2284\u20132300 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"1624_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769 (2018).","journal-title":"Cell"},{"key":"1624_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433\u2013447 (2018).","journal-title":"Cell"},{"key":"1624_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"The Cancer Genome Atlas Research Network","year":"2015","unstructured":"The Cancer Genome Atlas Research Network The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"1624_CR11","doi-asserted-by":"publisher","unstructured":"Zhu, X. et al. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI178604 (2024).","DOI":"10.1172\/JCI178604"},{"key":"1624_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128\u2013134 (2016).","journal-title":"Nat. Med."},{"key":"1624_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1158\/1541-7786.MCR-13-0546","volume":"12","author":"G Deb","year":"2014","unstructured":"Deb, G., Singh, A. K. & Gupta, S. EZH2: not EZHY (easy) to deal. Mol. Cancer Res. 12, 639\u2013653 (2014).","journal-title":"Mol. Cancer Res."},{"key":"1624_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u2013629 (2002).","journal-title":"Nature"},{"key":"1624_CR15","doi-asserted-by":"publisher","unstructured":"Wang, J. & Wang, G. G. No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21249501 (2020).","DOI":"10.3390\/ijms21249501"},{"key":"1624_CR16","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"K Xu","year":"2012","unstructured":"Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465\u20131469 (2012).","journal-title":"Science"},{"key":"1624_CR17","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","volume":"25","author":"J Kim","year":"2018","unstructured":"Kim, J. et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 25, 2808\u20132820 (2018).","journal-title":"Cell Rep."},{"key":"1624_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53874-2","volume":"15","author":"SS Chatterjee","year":"2024","unstructured":"Chatterjee, S. S. et al. Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nat. Commun. 15, 9755 (2024).","journal-title":"Nat. Commun."},{"key":"1624_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563\u2013577 (2016).","journal-title":"Cancer Cell"},{"key":"1624_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06177-2","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB\u2013EZH2\u2013TSP1 pathway in prostate cancers. Nat. Commun. 9, 4080 (2018).","journal-title":"Nat. Commun."},{"key":"1624_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan, V. B. et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat. Commun. 15, 6779 (2024).","journal-title":"Nat. Commun."},{"key":"1624_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.4070","volume":"22","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. ROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat. Med. 22, 488\u2013496 (2016).","journal-title":"Nat. Med."},{"key":"1624_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","volume":"20","author":"C Cai","year":"2011","unstructured":"Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457\u2013471 (2011).","journal-title":"Cancer Cell"},{"key":"1624_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436\u2013439 (2005).","journal-title":"Nature"},{"key":"1624_CR25","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-17-0496","volume":"77","author":"Y Liang","year":"2017","unstructured":"Liang, Y. et al. LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression. Cancer Res. 77, 5479\u20135490 (2017).","journal-title":"Cancer Res."},{"key":"1624_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGF\u03b2 in cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"1624_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nature09677","volume":"470","author":"Z Ding","year":"2011","unstructured":"Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269\u2013273 (2011).","journal-title":"Nature"},{"key":"1624_CR28","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1038\/s41388-022-02316-8","volume":"41","author":"P Gao","year":"2022","unstructured":"Gao, P. et al. PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer. Oncogene 41, 2945\u20132957 (2022).","journal-title":"Oncogene"},{"key":"1624_CR29","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1158\/1078-0432.CCR-07-1078","volume":"13","author":"S Lu","year":"2007","unstructured":"Lu, S. et al. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin. Cancer Res. 13, 5692\u20135702 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1624_CR30","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1093\/nar\/gkad043","volume":"51","author":"HY Jeon","year":"2023","unstructured":"Jeon, H. Y. et al. SMAD3 promotes expression and activity of the androgen receptor in prostate cancer. Nucleic Acids Res. 51, 2655\u20132670 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1624_CR31","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1093\/nar\/gkt1382","volume":"42","author":"D Wu","year":"2014","unstructured":"Wu, D. et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res. 42, 3607\u20133622 (2014).","journal-title":"Nucleic Acids Res."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01624-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:03:49Z","timestamp":1774418629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01624-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01624-9","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}